The use of sodium oxybate to treat narcolepsy - PubMed

Review

The use of sodium oxybate to treat narcolepsy

Geert Mayer. Expert Rev Neurother. 2012 May.

Abstract

Narcolepsy is a life-long neurodegenerative disorder that causes considerable impairment to quality of life. Until the 1970s, the treatment for one of the main symptoms, excessive daytime sleepiness, was restricted to stimulants, whereas the second core symptom, cataplexy, was treated with antidepressants, and the resultant fragmented night-time sleep with hypnotics. Sodium oxybate (Xyrem(®), UCB Pharma, Brussels, Belgium) is an efficacious drug for all three symptoms which improves the quality of life of narcoleptic patients. Owing to its metabolic pathway, there is very little pharmacokinetic interaction with other drugs. In combination with modafinil, some of its therapeutic benefits are enhanced. Adverse events and side effects are moderate when taken according to indication and as recommended. Essential limitations have to be considered before starting the treatment (sleep-related breathing disorders, alcohol intake, hypnotic and sedative comedication, and epilepsy). This article gives an overview of sodium oxybate, which has been US FDA approved for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy, and EMA approved for the treatment of narcolepsy-cataplexy.

Similar articles

• Sodium oxybate for narcolepsy.

  Scharf MB. Scharf MB. Expert Rev Neurother. 2006 Aug;6(8):1139-46. doi: 10.1586/14737175.6.8.1139. Expert Rev Neurother. 2006. PMID: 16893342 Review.

• Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.

  [No authors listed] [No authors listed] Prescrire Int. 2007 Jun;16(89):98-101. Prescrire Int. 2007. PMID: 17582923

• EFNS guidelines on management of narcolepsy.

  Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, Pollmächer T, Reading P, Sonka K; EFNS Task Force. Billiard M, et al. Eur J Neurol. 2006 Oct;13(10):1035-48. doi: 10.1111/j.1468-1331.2006.01473.x. Eur J Neurol. 2006. PMID: 16987156

• [Integrated treatment of the symptoms of narcolepsy-cataplexy syndrome with sodium oxybate].

  Poza-Aldea JJ. Poza-Aldea JJ. Rev Neurol. 2009 Jan 1-15;48(1):27-31. Rev Neurol. 2009. PMID: 19145563 Review. Spanish.

• Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy.

  Owen RT. Owen RT. Drugs Today (Barc). 2008 Mar;44(3):197-204. doi: 10.1358/dot.2008.44.3.1162240. Drugs Today (Barc). 2008. PMID: 18536781 Review.

Cited by

• Raising awareness about sleep disorders.

  Jaiswal SJ, Owens RL, Malhotra A. Jaiswal SJ, et al. Lung India. 2017 May-Jun;34(3):262-268. doi: 10.4103/0970-2113.205331. Lung India. 2017. PMID: 28474653 Free PMC article. Review.

• A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma.

  El-Habr EA, Dubois LG, Burel-Vandenbos F, Bogeas A, Lipecka J, Turchi L, Lejeune FX, Coehlo PL, Yamaki T, Wittmann BM, Fareh M, Mahfoudhi E, Janin M, Narayanan A, Morvan-Dubois G, Schmitt C, Verreault M, Oliver L, Sharif A, Pallud J, Devaux B, Puget S, Korkolopoulou P, Varlet P, Ottolenghi C, Plo I, Moura-Neto V, Virolle T, Chneiweiss H, Junier MP. El-Habr EA, et al. Acta Neuropathol. 2017 Apr;133(4):645-660. doi: 10.1007/s00401-016-1659-5. Epub 2016 Dec 28. Acta Neuropathol. 2017. PMID: 28032215 Free PMC article.

• Increased lucid dreaming frequency in narcolepsy.

  Rak M, Beitinger P, Steiger A, Schredl M, Dresler M. Rak M, et al. Sleep. 2015 May 1;38(5):787-92. doi: 10.5665/sleep.4676. Sleep. 2015. PMID: 25325481 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program